Wiliński B
Jagiellonian University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Wiliński B.
Pharmacological Reports | 2011
Wiliński B; Jerzy Wiliński; Eugeniusz Somogyi; Joanna Piotrowska; Marta Góralska
Hydrogen sulfide (H2S) is a crucial co-modulator of cardiovascular, nervous, digestive and excretory systems function. The pleiotropic action of atorvastatin exceeds simple 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibition and involves multiple biological mechanisms. This study assesses the influence of atorvastatin on the H2S tissue concentration in mouse brain, liver, heart and kidney. Twenty-four female CBA strain mice received an intraperitoneal injection. The mice were given one of the following solutions: 0.1 mg atorvastatin (5 mg/kg of body weight (b.w.)/day--group D1, n=8), 0.4 mg atorvastatin (20 mg/kg b.w./day--group D2, n=8) or a saline physiological control (0.2 ml--group C, n=8). A modified Siegel spectrophotometric method was used for the H2S tissue concentration measurements. There was a remarkable rise in the H2S concentration [μg/g] in the kidney (C: 5.26±0.09, D1: 5.77±0.11, p=0.0003; D2: 7.48±0.09, p<0.0001). There were also slight H2S tissue level changes in the brain (C: 1.61±0.01, D1: 1.75±0.03, p=0.0001; D2: 1.78±0.03, p<0.0001), the heart (C: 4.54±0.08, D1: 4.86±0.10, p=0.0027; D2: 4.56±0.07, p=0.6997) and the liver (C: 3.45±0.03, D1: 3.27±0.02, p=0.0001; D2: 3.31±0.02, p=0.0003). Our study supports the influence of atorvastatin on H2S tissue concentration in kidneys and other mouse organs.
Pharmacological Reports | 2010
Anna Bilska; Małgorzata Iciek; Inga Kwiecień; Karol Kaniecki; Magdalena Paliborek; Eugeniusz Somogyi; Joanna Piotrowska; Wiliński B; Marta Góralska; Zbigniew Srebro; Lidia Włodek
This study was designed to investigate the effect of aspirin (ASA) on anaerobic cysteine metabolism, which yields sulfane sulfur-containing compounds and hydrogen sulfide (H(2)S), in mouse liver and brain. In order to solve this problem, we determined the levels of sulfane sulfur and H(2)S, and the activities of cystathionase, the enzyme directly engaged in H(2)S synthesis, and rhodanese, the enzyme that catalyzes sulfane sulfur transfer to different acceptors. Moreover, we examined the effect of ASA on glial Gomori-positive cells (GGPC) in the brain that contain sulfur-rich glial Gomori-positive material (GGPM). The studies indicated an ASA-induced decrease in H(2)S levels in the brain and an increase in the liver. ASA-treated animals had lower cerebral levels of GGPM-containing GGPCs but the sulfane sulfur level was not affected. Conversely, the sulfane sulfur content in the liver dropped. ASA did not change cystathionase and rhodanese activity in either organ. The obtained results revealed that ASA was able to influence anaerobic cysteine metabolism, leading to the formation of sulfane sulfur and H(2)S in the mouse liver and brain, and to affect the numbers of GGPM-containing GGPCs.
Biology and medicine | 2015
Tomasz Kameczura; Marek Rajzer; Artur Mazur; Stanislaw Bartus; Sebastian Stec; Piotr Kukla; Tomasz Gziut; Jerzy Wiliński; Anna Kameczura; Wiliński B; Marta Lechowicz; Blessed Marta; Malopolska Burns
Introduction: Regular physical exercise appears to potentiate the effects of pharmacological treatment for arterial hypertension. As such, regular exercise is recommended as an adjuvant treatment in hypertensive subjects by both European and American guidelines. Crucially, however, there are no precise recommendations on the type of physical exercise and how it should be instituted. Aerobic Interval Training (AIT) is a new and novel type training that appears to be beneficial to patients suffering from various medical conditions. There is a distinct lack of evidence on how it affects arterial hypertension. The aim of this study was to evaluate the influence of a 5 month period of regular AIT on blood pressure, carotid femoral pulse wave velocity (PWV) and applanation tonometry indexes in patients previously treated pharmacologically for mild or moderate arterial hypertension. Materials and Methods: The study group consisted of 60 hypertensive subjects (30 males, 30 females) (age 54.45 ± 8.52 years) who had previously undergone at least 2 years of combined anti-hypertensive therapy and who had well controlled hypertension, i.e. below 140/90 mmHg. Their pharmacological treatment did not change during the study period. The study group was randomly divided into 2 subgroups. In the first group (G1), AIT was undertaken for 5 months (40 professional AIT sessions performed two times per week in 50 minute sessions) and followed a specially developed program. The second control group (G2), did not attend any training sessions but received medical advice on how to maintain physical activity as outlined by JNC hypertension guidelines. During the baseline visit and then at five months (final visit), both groups underwent testing for office BP, PWV and applanation tonometry indexes using the SphygmoCor® device and the Complior® device. Results: During the baseline visit, we found no significant difference between the two groups in the age of the subjects, their office SBP, DBP, PWV and applanation tonometry indexes. After five months of regular AIT, the subjects in G1 were found to have an office SBP of 132.8 ± 6.1 mmHg (vs. 128.9 ± 5.9 mmHg, p<0.05), a DBP of 80.5 ± 4.1 mmHg (vs. 77.8 ± 2.3 mmHg, p<0.05), PWV Complior® of 10.3 ± 1.18 m/s (vs. 9.26 ± 1.11 m/s, p<0.05), and a PWV SphygmoCor® of 8.37 ± 1.03 mmHg (vs. 7.48 ± 0.97 mmHg, p<0.05). Moreover we noticed significant changes in applanation tonometry indexes, such as central SBP, central PP, central and peripheral AIx (all p<0.05) after 5 month. In the G2 group, SBP, DBP, applanation tonometry indexes and PWV did not significantly change between measurements taken at baseline and during the final visit. Conclusion: A relatively short period of regular AIT significantly decreased blood pressure, pulse wave velocity, and most applanation tonometry indexes in hypertensive subjects also undertaking pharmacological treatment.
Folia medica Cracoviensia | 2006
Srebro Z; Eugeniusz Somogyi; Wiliński B; Góralska M; Jerzy Wiliński; Sura P
Folia medica Cracoviensia | 2008
Jerzy Wiliński; Eugeniusz Somogyi; Góralska M; Wiliński B; Czarnecka D
Folia Biologica | 2011
Wiliński B; Jerzy Wiliński; Eugeniusz Somogyi; Marta Góralska; Joanna Piotrowska
Folia Biologica | 2012
Wiliński B; Jerzy Wiliński; Eugeniusz Somogyi; Joanna Piotrowska; Włodzimierz Opoka
Folia medica Cracoviensia | 2011
Wiliński B; Jerzy Wiliński; Eugeniusz Somogyi; Piotrowska J; Góralska M
Folia medica Cracoviensia | 2015
Jerzy Wiliński; Marta Lechowicz; Kameczura T; Głowacki M; Kameczura A; Chrapusta A; Wiliński B
Folia Biologica | 2008
Piotr Sura; Zbigniew Srebro; Wiliński B; Marta Góralska